-
Aesculap (Center Valley, Pennsylvania) said it has been awarded a 24-month agreement with Premier for a complete array of neurosurgery products for the treatment of strokes, tumors and other cerebrovascular conditions. The multi-source agreement, in effect since Jan. 1, is Premiers first contract for neurosurgical products.
-
After a period of about nine months apparently on hold, the clinical trial of the AbioCor replacement heart made by Abiomed (Danvers, Massachusetts) picked up speed last month, with the company reporting a second implant in January, the two most recent at Jewish Hospital in Louisville, Kentucky.
-
A second player has officially arrived in the drug-eluting stent market with a European approval. Boston Scientific (BSX; Natick, Massachusetts) received the CE mark for its Taxus stent system in late January, joining Johnson & Johnsons (J&J; New Brunswick, New Jersey) Cordis (Miami Lakes, Florida) unit in the still-elite coated-stent club.
-
A Medicare advisory panel recommendation to cover implantable cardioverter defibrillators (ICDs) could be a major victory for companies such as Guidant (Indianapolis, Indiana), Medtronic (Minneapolis, Minnesota) and St. Jude Medical (St. Paul, Minnesota).
-
Centerpulse (Zurich, Switzerland) reported closing on the previously announced sale of its Carbomedics (Austin, Texas) and Mitroflow (Richmond, British Columbia) mechanical and tissue heart valve businesses to Snia SpA (Milan, Italy), as planned, for about $116 million.
-
Traditional cardiac pacemakers are continuing to improve, particularly in regard to new applications. We have already seen pacemakers with memories from Biotronik (Berlin, Germany) and other companies that can be downloaded by telephone to provide historic information enabling the cardiologist to monitor at a distance.
-
WASHINGTON While the approval of drug-eluting stents is practically a certainty, interventional radiologists and cardiologists alike are wasting no time in looking to the future and what it may hold in terms of breakthrough treatments. That future could be one without the drug-coated stent.
-
In half-hour presentations and lengthier panel discussions, cardiovascular technology company officials, clinicians and industry analysts elevated the dispersal of information to a new art form during two bellwether investor conferences held on opposite coasts last month. The JPMorgan Healthcare Conference, holding its traditional early-January spot as lid-lifter for a years worth of such events, drew its usual throng to the venerable Westin St. Francis Hotel in San Francisco.
-
-
When the patient presents with arrhythmia, the diagnosis of Wolff-Parkinson_White (WPW) may not be known nor apparent due to the arrhythmia. The rhythm scenarios and/or features should suggest, not confirm, the diagnosis of WPW.
